hrp0095p1-392 | Thyroid | ESPE2022

Clinical Features, Risk Classifications and Long-Term Follow Up Of Childhood Differentiated Thyroid Cancer(DTC): A Single Reference-Center Experience

Aycan Zehra , Çetin Sirmen Kızılcan , Zeynep Şıklar , Elif Özsu , Fitöz Suat , Ceyhan Koray , Yağmurlu Aydın , Göllü Bahadır Gülnur , Ünal Emel , Taşyıldız Nurdan , Kır Metin , Soydal Çiğdem , Berberoğlu Merih

Background: Thyroid cancers are rare in childhood. ATA guideline (Pediatric section) has been applied in daily practice since 2015. It is very significant to accurately predict the risk in the management of differentiated thyroid cancer(DTC). For this purpose, we shared our single center-20-year-experience about the follow-up features and management of childhood and adolescent thyroid cancer. We aimed to evaluate the dynamic risk stratification (DRS) and the o...

hrp0092p2-103 | Diabetes and Insulin | ESPE2019

Evaluation of the Association of Glutamic Acid Decarboxylase Antibody and Limbic Encephalitis in Children with Type 1 Diabetes Mellitus

Ugurlu Aylin Kilinç , Bideci Aysun , Arhan Ebru , Döger Esra , Serdaroglu Ayse , Tekin Orgun Leman , Soysal Acar Azime Sebnem , Çamurdan Orhun , Cinaz Peyami , Gücüyener Kivilcim

Glutamic acid decarboxylase (GAD) is the enzyme that catalyzes the conversion of L-glutamat into GABA, one of the classical neurotransmitters with neuroinhibitory function. GAD is present in GABAergic neurons and in pancreatic beta cells. It is remarkable that Anti-GAD antibody(Anti-GADab) can have different disease manifestations, i.e., Type 1 diabetes mellitus (T1DM), Stiff-Person Syndrome, limbic encephalitis (LE), epilepsy. Cooccurence of T1DM and LE is reported in the lit...